Showing results (81-90 of 130) with videos related to
Sort By:
Pageof 13
Methods in Molecular Biology (Clifton, N.J.)|July 15, 2009
ArrayTrack: an FDA and public genomic toolHong Fang, Stephen C Harris, Zhenjiang Su, et al.Methods in Molecular Biology (Clifton, N.J.)|August 30, 2017
ArrayTrack: An FDA and Public Genomic ToolHong Fang, Stephen C Harris, Zhenjiang Su, et al.Archives of Toxicology|June 25, 2014
A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' modelMinjun Chen, Chun-Wei Tung, Qiang Shi, et al.Journal of Chemical Information and Modeling|March 29, 2017
Integrating Drug's Mode of Action into Quantitative Structure-Activity Relationships for Improved Prediction of Drug-Induced Liver InjuryLeihong Wu, Zhichao Liu, Scott Auerbach, et al.Journal of Proteome Research|April 11, 2006
Metabonomic study of aristolochic acid-induced nephrotoxicity in ratsMinjun Chen, Mingming Su, Liping Zhao, et al.Chinese Medicine|March 11, 2008
Metabolic profiling reveals therapeutic effects of Herba Cistanches in an animal model of hydrocortisone-induced 'kidney-deficiency syndrome'Yunping Qiu, Minjun Chen, Mingming Su, et al.Hepatology (Baltimore, Md.)|July 18, 2024
Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injuryAyoOluwa O Olubamiwa, Tsung-Jen Liao, Jinwen Zhao, et al.Chemical Research in Toxicology|January 22, 2008
Mass spectrometry-based metabolic profiling of rat urine associated with general toxicity induced by the multiglycoside of Tripterygium wilfordii Hook. fMinjun Chen, Yan Ni, Hongquan Duan, et al.Archives of Toxicology|March 5, 2021
Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approachAndres Gonzalez-Jimenez, Ayako Suzuki, Minjun Chen, et al.Technology in Cancer Research & Treatment|May 6, 2024
A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung CancerCan Chen, Minjun Chen, Yuju Bai, et al.Pageof 13